Moxetumomab Pasudotox-Tdfk for Hairy Cell Leukemia With Robert Kreitman, MD

Hairy cell leukemia (HCL) comprises only 2% of all leukemias and has limited treatment options. In a phase 3 trial, a team of researchers led by Robert Kreitman, MD, a medical oncologist at the National Cancer Institute, found that moxetumomab pasudotox-tdfk, a recombinant CD22-directed cytotoxin, achieved a high rate of durable response in patients with relapsed/refractory HCL. Dr. Kreitman presented the long-term follow-up results of the trial at the American Society of Hematology (ASH) Annual...
Continue reading

Nail Salon Workers Exposed to Cancer-Causing Chemicals

Nail salon technicians are exposed to high levels of volatile organic compounds, many of which are in high enough concentrations and toxic enough to cause cancer. In order to understand the severity of this situation, researchers measured the levels of various chemicals in six different salons across Colorado and found that many chemicals exceeded the safe limit, putting workers at an increased risk of developing malignancies. For this study, published in Environmental Pollution, the investigato...
Continue reading

Leukemia: Genetic “Map” Helps Clinicians Treat Patients

With unknown risk factors and a varied response to treatment, acute myelogenous leukemia (AML) can be a difficult cancer to treat. In order to improve the understanding of this disease, researchers at The University of Texas at San Antonio (UTSA) and the University of Texas MD Anderson Cancer Center created the AML Proteome Atlas, a database derived from MetaGalaxy analyses that contains the proteomic profiling of 205 patients with AML and 111 leukemic cell lines. "Acute myelogenous leukemia pre...
Continue reading

Killing Leukemia Cells by Disrupting Amino Acid Consumption

Researchers at Winship Cancer Institute of Emory University found that inhibiting amino acid metabolism hinders leukemia cell growth. The investigators report that ASCT2, a transporter enzyme that carries amino acids into cells, is a potential therapeutic target for cancer. "So far, little progress has been made in finding therapeutic targets in amino acid metabolic pathways that can be harnessed to kill cancer cells but spare normal cells," remarked Cheng-Kui Qu, MD, PhD, Professor in the Depar...
Continue reading

Nurses’ Handling of Hazardous Drugs: An Interview With Christopher Friese, PhD, RN, AOCN®, FAAN

When nurses do not wear appropriate personal protective equipment while administering chemotherapy drugs, they risk exposure, which increases their chances of developing leukemia and other cancers, adverse reproductive outcomes, and chromosomal damage. In this interview with i3 Health, Dr. Friese provides insight regarding his study of an intervention to improve nurses' handling of hazardous drugs, the implications of unsafe handling, and potential solutions to improve the safety of nurses who a...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.